|By Business Wire||
|May 7, 2014 10:04 AM EDT||
Please replace the release with the following corrected version due to multiple revisions.
The corrected release reads:
MOLECULARHEALTH GUIDES BETTER CANCER TREATMENTS WITH TWO NEW DIAGNOSTIC TESTS
TreatmentMAP platform combines precision medicine with advanced data analytics to guide patients and physicians to the safest, most effective cancer treatment options
Backed by more than eight years of research and development, MolecularHealth announced today the official launch of TreatmentMAP™, its cancer treatment decision support offering. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic tests to identify the optimal, safest treatment options for each individual patient. For the first time, cancer patients and their medical teams will have access to actionable information to guide the selection of targeted cancer treatments, presented in a clear and understandable way. TreatmentMAP became commercially available in Europe and the U.S. in April.
The company has two available versions of its offering:
- TreatmentMAP Targeted Panel is the largest gene panel commercially available today, with over 500 genes that cover several thousand variants and have been determined to have the most clinical impact in cancer, and are therefore most likely to make a difference in treatment outcome.
- TreatmentMAP Whole Exome, the first commercially available whole exome analysis for cancer, taking a comprehensive look at a patient’s genetic profile by examining the genes of both the tumor and germline.
Both testing options incorporate MolecularHealth’s SafetyMAP™, a proprietary identification of drug target safety or resistance effects, using the FDA’s Adverse Event Reporting Systems (AERS) as an input for analysis. Through MolecularHealth’s five-year research collaboration agreement with the FDA, MolecularHealth incorporates key data from AERS into SafetyMAP, providing the first drug safety analysis that combines adverse event information with molecular knowledge about drug activity within a patient. This ensures that treatment options will not only be effective, but won’t have unintended negative consequences for patients.
“I believe that the future of medicine lies in our ability to interpret seemingly disparate information,” said Lloyd Everson, M.D., co-CEO of MolecularHealth. “With the technology now at our disposal, there are mountains of data constantly being churned out of labs and clinical trials – but until recently, it was an unwieldy task to do anything productive with that information. TreatmentMAP allows us to pull in all of that data and make it truly usable.”
TreatmentMAP tests can be ordered in the United States and in Europe. In the U.S., a patient’s oncologist or pathologist sends a tumor sample to MolecularHealth’s CLIA-certified NGS lab in The Woodlands, Texas. Once the sample is sequenced, data on the tumor’s DNA, along with additional medical information on the patient, is fed into the company’s automated analytics platform. This platform cross-references patient-specific data with the latest peer-reviewed evidence, clinical trials, and other sources. A simple-to-understand report is delivered to the patient’s medical team, highlighting the treatment options that are most likely to be both effective and safe.
“We are still trying to understand cancer, and as an oncologist I have observed that the most effective cancer therapies are those that precisely target the unique biology of an individual patient's tumor,” said Joyce O’Shaughnessy, M.D., co-chair of breast cancer research at US Oncology and Baylor-Sammons Cancer Center. “TreatmentMAP offers new insights into the molecular drivers of a tumor, leading to expanded therapeutic options and greater chance for therapy response.”
“As a pathologist, I’m happy to have a company joining the molecular diagnostic space that’s more pathologist-friendly than some of the competition in this field,” said Thomas Wheeler, M.D., chairman of the Department of Pathology & Immunology at Baylor College of Medicine. “The market can only benefit from having more options to meet the needs of individual patients, and from what I’ve seen, MolecularHealth’s reports are not only more robust, but focus on the elements that are most important when determining a treatment path for a patient.”
Drs. O’Shaughnessy and Wheeler are members of the MolecularHealth advisory board.
For more information on TreatmentMAP and how to order a test, please visit MolecularHealth’s website.
MolecularHealth is a leading biomedical company transforming molecular data into actionable clinical information for the most efficient and safest cancer treatment options for each individual cancer patient. By using advanced proprietary tumor analysis and interpretation to match patient-specific genetic and molecular test findings to the current state of the world’s biomedical knowledge about cancer, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, and SAP AG. The company is headquartered in Heidelberg, Germany. U.S. headquarters, including a CLIA-certified NGS lab, are located in The Woodlands, Texas. The company also has offices in Boston, Mass.
Feb. 20, 2017 02:45 PM EST Reads: 396
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Feb. 20, 2017 02:15 PM EST Reads: 1,084
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Feb. 20, 2017 01:30 PM EST Reads: 399
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Feb. 20, 2017 01:15 PM EST Reads: 369
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Feb. 20, 2017 01:00 PM EST Reads: 839
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Feb. 20, 2017 01:00 PM EST Reads: 1,195
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
Feb. 20, 2017 01:00 PM EST Reads: 5,854
Feb. 20, 2017 01:00 PM EST Reads: 10,046
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you...
Feb. 20, 2017 12:45 PM EST Reads: 1,017
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Feb. 20, 2017 12:45 PM EST Reads: 958
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
Feb. 20, 2017 12:45 PM EST Reads: 4,287
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
Feb. 20, 2017 12:30 PM EST Reads: 472
Column Technologies exhibited at SYS-CON's @DevOpsSummit at Cloud Expo, which took place at the Javits Center in New York City, NY, in June 2016. Established in 1998, Column Technologies is a global technology solutions provider with over 400 employees, headquartered in the United States with offices in Canada, India, and the United Kingdom. Column Technologies provides “Best of Breed” technology solutions that automate the key DevOps principals and help our customers meet today’s DevOps and Dig...
Feb. 20, 2017 12:15 PM EST Reads: 806
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Feb. 20, 2017 12:00 PM EST Reads: 1,150
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Feb. 20, 2017 11:30 AM EST Reads: 1,737